Russia’s Sputnik V gets Emergency Use authorisation nod in India

The decision comes after the Drugs Controller General of India (DCGI)'s SEC met today to take up Sputnik V application for EUA in India.

Medicine Injection Vaccine
Picture: Pixabay

New Delhi: Russia’s Sputnik V got approval from the Subject expert committee (SEC) for Emergency Use Authorisation (EUA), making it the third C-19 vaccine to get clearance in India.

According to sources, the SEC approved Dr Reddy’s application for EUA to Sputnik V. The decision comes after the Drugs Controller General of India (DCGI)’s SEC met today to take up Sputnik V application for EUA in India.

Dr Reddy’s Laboratories, last week sought the government’s approval for the vaccine to be used in India. The Russian Direct Investment Fund (RDIF) partnered with Dr Reddy’s in September 2020 to conduct clinical trials of Sputnik V in India.

Medicine Injection
Picture: Pixabay

DCGI had then sought additional data from drugmaker Dr Reddy’s Laboratories on its Sputnik V C-19 vaccine trial.

India is currently manufacturing two C-19 vaccines: Serum Institute of India’s locally-made Oxford C-19 vaccine ‘Covishield‘ and Bharat Biotech‘s indigenously manufactured Covaxin.

Also read:

Latest Notifications: Testing Laboratories

India bans export of Remdesivir drug

NATCO gets tentative USFDA nod for Ibrutinib tablets

First AI device to help detect colon cancer gets USFDA nod

On Sunday, government sources said that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers.

“India currently has two C-19 vaccines being manufactured locally: Covishield and Covaxin, and we can expect five more vaccines by Q3 2021.

These vaccines are:

Sputnik V vaccine (in collaboration with Dr. Reddy’s)
Johnson & Johnson vaccine (in collaboration with Biological E)
Novavax vaccine (in collaboration with Serum India)
Zydus Cadila’s vaccine and
Bharat Biotech’s Intranasal Vaccine.

Safety and efficacy are the Union government’s primary concerns while granting emergency use authorisation (EUA) to any C-19 vaccine in the country,” said the sources.

The Russian vaccine has an effectiveness of 91.6 per cent. Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

The EUA of Sputnik V comes at a time when India is facing the second wave of C-19 pandemic with the number of new cases increasing each day.

Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates